Posted: May 10, 2007
Whereas Merck claims Gardasil is 98% effective against 2 types of HPV virus that cause cervical cancer, this drops to 17% when looking at data from another group and the authors of a NEJM editorial called the vaccine's overall efficacy against precancerous lesions of the cervix "modest."
Perhaps it's time for Merck to change the Gardasil ads to be a little closer to the recent type of ad that Pfizer ran for Celebrex -- at least more transparent about the effectiveness of Gardasil and answering some of the questions that are now being raised.
For more on this, read today's post to Pharma Marketing Blog.
For more posts in related topic areas, see:
If you wish to receive notice by email whenever a post is made to Pharma Marketing Blog, please subscribe.
| Return to Pharma Marketing Blog Topics |